Adults with atopic dermatitis treated with upadacitinib had fewer major adverse cardiovascular events compared with ...

Alisha Bridges has lived with Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) for almost three decades. At seven years old, she started experiencing itchy, flaky, inflamed skin, which led to a ...

Additional safety signals have been identified with apremilast, with some adverse events specific to certain patient populations.

John Mauceri, an award-winning music conductor, author, and recording artist, is celebrating his return to the stage in ...

This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in ...

Market LaunchFormycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada 27.05.2025 / 14:30 CET/CESTThe issuer is solely responsible for ...

Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfi™ is indicated for the treatment of several serious ...

Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd (BSE: 532520, today announced that the UK’s ...

The action expands upon the company’s October 2024 revenue forecast of around $1 billion in sales during the first year, with ...

John Mauceri had a complicated health history, but his sudden swelling and fatigue left his team of doctors stumped.

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...